Primary hepatic (extranodal) lymphoma: utility of [18F]fluorodeoxyglucose-PET/CT

Seshadri, Nagabhushan; Ananthasivan, Rupa; Kavindran, Rashmi; Givvimani, Srikanth; Chandra, Suresh

doi:10.1102/1470-7330.2010.0028

Cited by 12 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, diffusion-weighted images show the difference between benign and malignant liver tumors showing the possibility of contribution to distinguish the malignant lesion by quantifying diffusion effects [7,8].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic imaging of hepatic lymphoma

Abé

Kamimura

Kawai

et al. 2015

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Diagnostic imaging of hepatic lymphoma

Abé

Kamimura

Kawai

et al. 2015

Clinics and Research in Hepatology and Gastroenterology

View full text Add to dashboard Cite

“…In one of these [33], the authors suggested that PHL can be suspected on the basis of a patient's history, in particular when HCV-related chronic liver inflammation is known to be present and some biochemical parameters are out of range (increased alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and lactate dehydrogenase levels).…”

Section: Fdg In Hepatic Lymphomamentioning

confidence: 99%

FDG and other radiopharmaceuticals in the evaluation of liver lesions

Grassi

Morigi

Nanni

et al. 2014

Clin Transl Imaging

View full text Add to dashboard Cite

Liver nodules are common findings in medical practice, both in patients with and in those without chronic liver disease. These lesions have to be interpreted according to clinical history and biochemical findings. Conventional imaging (US, CT and MRI) is still the gold standard for evaluating liver nodules, while diagnostic flowcharts do not currently include PET/CT. Since the 1990s many studies have been conducted to assess a possible role for FDG PET or PET/ CT in several liver pathologies. According to the literature, FDG PET (and later PET/CT) could be useful in detecting, staging and grading hepatocellular carcinoma, often leading to a change in therapy, and may even detect intrahepatic cholangiocarcinoma with adequate sensitivity. Moreover, FDG can allow more accurate staging of hepatic involvement deriving from other tumors (often underestimated by conventional imaging) and, therefore, more appropriate therapy in affected patients. Finally, FDG PET can also be used to evaluate 90 Y microsphere therapy response. Other conditions (e.g., primary hepatic lymphoma when conventional imaging is inconclusive) may benefit from the use of FDG PET/CT, while benign lesions (e.g., focal nodular hyperplasia) show low FDG avidity. As regards non-FDG tracers, choline and acetate (ACE) have been evaluated in comparison with FDG and found to show good efficacy in detecting and staging wellor moderately differentiated HCC. However, their sensitivity in poorly differentiated HCC is very low, suggesting that dualtracer investigation (FDG and choline/FDG and ACE) could be useful when non-invasive grading is required. Despite promising results, PET evaluation of liver nodules still seems to be far from routine application, mostly because of costrelated issues.

show abstract

“…As for cholangiocarcinoma, the sensitivity of FDG PET is high (> 90%) for the intrahepatic subtype and less so for the extrahepatic subtype (about 60%) [24]. Uncommon liver malignancies like lymphoma, both primary [25] and secondary [26], and angiosarcoma [27] have also been reported to show increased FDG uptakes.…”

Section: Solitary Uptakementioning

confidence: 99%